BPC-157 + TB-500 Blend (Wolverine Stack)

Two peptides in equal weights: BPC-157, the 15-residue gastric-derived peptide, and TB-500, here the full 43-residue thymosin beta-4. Vials come as 5mg + 5mg or 10mg + 10mg. Because it is a mixture, the blend has no CAS number or formula of its own; each component keeps its own. You may also see it listed as BPC 157 TB 500, BPC157 TB500 or the BPC/TB-500 blend.

It is an informal nickname borrowed from the Marvel comic character known for healing almost instantly, and it grew up in online research and enthusiast communities rather than in scientific papers. “Stack” is slang for compounds combined in one protocol. The label is loose enough that a recent analysis of clinical notes called BPC-157 on its own the “Wolverine peptide”, which is why we spell out both components on the label.

It is the full-length protein. The seven-residue fragment Ac-LKKTETQ, which anti-doping papers often call TB-500, has a molecular weight under 900 g/mol, whereas the thymosin beta-4 in this blend weighs about 4,963.5 g/mol. That difference is large enough to show immediately in mass spectrometry, so the identity data on the Certificate of Analysis settle which form is present.

On ingredients alone, that is a fair description. GLOW pairs the same two peptides, at 10mg apiece, with 50mg of GHK-Cu, so the copper peptide makes up most of the vial and steers the research towards matrix remodelling. The Wolverine Stack drops it entirely, and its 10mg + 10mg fill matches GLOW’s two repair peptides weight for weight, which makes the pair a natural comparison arm in a study that also uses GLOW.

Thymosin beta-4 brings actin biology: it holds actin monomers in reserve inside cells, and its literature follows cell migration, new vessel growth and, when released outside cells, signalling to surrounding tissue. BPC-157 brings a separate line of vascular and growth-factor receptor work. Studying them together lets one experiment ask whether those two routes add up, overlap or interfere.

Once, in rats. A four-group Achilles tendon repair study compared controls, BPC-157 alone, TB-500 alone and the combination over four weeks. TB-500 alone produced the clearest biomechanical and histology gains, and the pair improved one histology score over controls but showed no extra benefit beyond either single peptide. One small study cannot close the question, but it sets a useful benchmark.

Groups running animal series or several treatment arms, where the larger fill means half as many vials to reconstitute for the same total peptide. The 5mg + 5mg fill is the economical route into cell-migration, tube-formation or explant work, where working concentrations are small. Single vials suit a pilot; the five- and ten-vial boxes lower the cost per vial and keep a run of experiments on one production lot.

Not equal numbers. Thymosin beta-4 is about three and a half times the mass of BPC-157, so a 5mg + 5mg vial contains roughly 3.5 micromoles of BPC-157 and 1.0 micromole of thymosin beta-4, a molar ratio near 3.5 : 1. Studies that report concentrations in molar units should convert each component separately.

Whenever the design needs single-peptide arms, which any properly controlled combination study does, or when the ratio itself is under investigation. The blend is ideal for the combined arm, giving the same proportions in every vial; the standalone peptides cover the comparison groups and any ratio other than one-to-one by weight.

At minimum, four: vehicle, BPC-157 alone, TB-500 alone and the combination, ideally with matched amounts of each peptide in the single and combined arms. This two-by-two layout is the only way to tell an additive or synergistic effect from one peptide simply doing the work. Randomisation, blinded scoring and enough animals per group to detect a modest difference all matter; the first rat study used eight per group, a size better suited to spotting large effects than subtle ones.

Pick measures that map on to each peptide’s strengths. Load to failure and stiffness capture mechanical recovery; histology scores such as Bonar or Movin, Sirius red birefringence and collagen I/III staining describe tissue quality; vessel counts or perfusion imaging cover blood supply; and scratch or transwell assays test cell migration in culture. Including a later time point helps, because early and late repair can favour different components.

Size does most of the work. In reversed-phase HPLC the two chains have very different lengths and surface chemistry, so they elute as two well-resolved peaks. In electrospray mass spectrometry BPC-157 appears as one or two low charge states, while thymosin beta-4 spreads into a ladder of multiply charged ions, for example near m/z 1,241.9, 993.7 and 828.3 for the 4+, 5+ and 6+ ions, which deconvolute to its intact mass. Because methionine 6 is the only oxidisable residue of note, a companion signal 16 Da heavier on the thymosin side points to methionine sulphoxide, which is worth tracking since oxidised thymosin beta-4 behaves differently in actin assays.